Pharmacological therapy of acute heart failure: what is available now and what is expected in future
https://doi.org/10.21292/2078-5658-2020-17-2-29-37
Abstract
The objective: to present an overview of current approaches to pharmacological therapy of acute heart failure (AHF).
Results: the discussion focuses on drugs that are currently available and being actively studied in ongoing clinical trials. Disadvantages and adverse reactions of modern medications for the treatment of AHF are presented. Vasodilators cannot be used for arterial hypotension; inotropic drugs (catecholamines and phosphodiesterase inhibitors) produce proarrhythmogenic effect, increase the myocardial oxygen demand, and may cause excessive vasodilation. The mortality in patients receiving these medications and vasopressor agents remains high. The article presents data on the positive hemodynamic effect of levosimendan calcium sensitizer in patients with severe heart failure, as well as in some other categories of cardiac surgery patients but it emphasizes that the attitude to its effect on long-term survival of patients remains ambiguous. To remove contradictions, it is necessary to conduct the trial that is properly designed and does not contradict the indications and contraindications noted in the instructions for its use. It is suggested that in such trials, in particular, it is advisable to use temporary endpoints of the trial that are comparable to the duration of action of the studied drugs. In the nearest future, data will be obtained that will allow evaluating the possibility of wide clinical use of new groups of drugs: cardiac myosin activators, natriuretic peptides, vasopressin receptor inhibitors, drugs that affect the expression of calcium ATPase in the cardiac sarcoplasmic network (SERCA2a), including those developed using genetically engineered technologies.
About the Author
A. A. Eremenko
Russian Surgery Research Center named after B.V. Petrovsky
Russian Federation
Russian Federation
Aleksandr A. Eremenko - Doctor of Medical Sciences, Professor, Correspondent Member of the Russian Academy of Sciences, Head of Intensive Care Department II (Cardiac Intensive Care II)
2, Abrikosovsky Lane, GSP-1, Moscow, 119991
References
1. Babaev M.А., Eremenko А.А., Dymova O.V. et al. The use of levosimendan in the preparation of patients with chronic heart failure for cardiac surgery. Rossiysky Kardiologicheskiy Journal, 2017, no. 3 (143), pp. 59-62. (In Russ.)
2. Bautin А.А., Ksendikova А.V., Belolipetskiy S.S. et al. On the possibility of using pharmacological indices to predict the course of the postoperative period of cardiac surgery. Vestnik Intensivnoy Terapii Im. А.I. Saltanova, 2019, no. 2, pp. 66-74. (In Russ.) doi: 10.21320/1818-474X-2019-2-66-74.
3. Kozlov I.А., Krichevskiy L.А. Evaluation of levosimendan efficacy in cardiac surgery. Messenger of Anesthesiology and Resuscitation, 2017, vol. 14, no. 4, pp. 81-82. (In Russ.) //doi.org/10.21292/2078-5658-2017-14-4-81-82.
4. Mareev V.Yu., Fomin I.V., Аgeev F.T. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologia, 2018, no. 58 (S6). (In Russ.) doi: 10.18087/cardio.2475.
5. Polyakov D.S., Fomin I.V., Valikulova F.Yu. et al. The EPOCH-CHF epidemiological program: decompensated chronic heart failure in real-life clinical practice (EPOCH-D-CHF). Journal Serdechnaya Nedostatochnost, 2016, vol. 17, no. 5, pp. 299-305. (In Russ.) doi:10.18087/rhfj. 2016.5.22.
6. Agostoni P., Farmakis D.T., García-Pinilla J.M. et al. Haemodynamic balance in acute and advanced heart failure: an expert perspective on the role of Levosimendan. Card Fail Rev., 2019, vol. 5, no. 3, pp. 155‒161. doi: 10.15420/cfr.2019.01.R1. eCollection 2019 Nov.
7. Bistola V., Simitsis P., Farmakis D. et al. Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure. Clin. Res. Cardiol., 2018, vol. 107, no. 1, pp. 76‒86. doi: 10.1007/s00392-017-1161-7. Epub 2017 Sep 18.
8. Chen Q.H., Zheng R. Q., Lin H. et al. Effect of levosimendan on prognosis in adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. Crit. Care, 2017, vol. 21, no. 1, pp. 253. doi: 10.1186/s13054-017-1848-1.
9. Cholley B., Levy B., Fellahi J.L. et al. Levosimendan in the light of the results of the recent randomized controlled trials: an expert opinion paper. Crit. Care, 2019, vol. 23, no. 1, pp. 385. doi: 10.1186/s13054-019-2674-4.
10. De Backer D., Biston P., Devriendt J. et al. SOAP II Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N. Engl. J. Med., 2010, vol. 362, no. 9, pp. 779‒789. doi: 10.1056/NEJMoa0907118.
11. Farmakis D., Agostoni P., Baholli L. et al. A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus. Int. J. Cardiol., 2019, vol. 297, pp. 83‒90. doi: 10.1016/j.ijcard.2019.09.005. Epub 2019 Sep 6.
12. Fedele F., Severino P., Calcagno S. et al. Heart failure: TNM-like classification. J. Am. Coll. Cardiol., 2014, vol. 63, no. 19, pp. 1959‒1960. doi: 10.1016/j.jacc.2014.02.552. Epub 2014 Mar 19.
13. Forssmann W., Meyer M., Forssmann K. The renal urodilatin system: clinical implications. Cardiovasc. Res., 2001, vol. 51, no. 3, pp. 450‒462. doi: 10.1016/s0008-6363(01)00331-5.
14. Gheorghiade M., Gattis W.A., O'Connor C. M. et al. Acute and chronic therapeutic impact of a vasopressin antagonist in congestive heart failure (ACTIV in CHF) investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA, 2004, vol. 291, no. 16, pp. 1963‒1971. doi: 10.1001/jama.291.16.1963.
15. Iyengar S., Feldman D.S., Trupp R. et al. Nesiritide for the treatment of congestive heart failure. Expert Opin Pharmacother., 2004, vol. 5, no. 4, pp. 901‒907. doi: 10.1517/14656566.5.4.901.
16. Jacky A., Rudiger A., Krüger B. et al. Comparison of Levosimendan and Milrinone for ECLS weaning in patients after cardiac surgery-a retrospective before-and-after study. J. Cardiothorac. Vasc. Anesth., 2018, vol. 32, no. 5, pp. 2112‒2119. doi: 10.1053/j.jvca.2018.04.019. Epub 2018 Apr 6.
17. Keating G. M., Goa K. L. Nesiritide: a review of its use in acute decompensated heart failure. Drugs, 2003, vol. 63, no. 1, pp. 47‒70. doi: 10.2165/00003495-200363010-00004.
18. Konstam M.A., Gheorghiade M., Burnett J.C.Jr. et al. Efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA, 2007, vol. 297, no. 12, pp. 1319‒1331. Epub. 2007 Mar 25. doi: 10.1001/jama.297.12.1319.
19. Léopold V., Gayat E., Pirracchio R. et al. Epinephrine and short-term survival in cardiogenic shock: an individual data meta-analysis of 2583 patients. Intens. Care Med., 2018, vol. 44, no. 6, pp. 847‒856. doi: 10.1007/s00134-018-5222-9. Epub 2018 Jun 1.
20. Levy B., Clere-Jehl R., Legras A. et al. Collaborators. Epinephrine versus norepinephrine for cardiogenic shock after acute myocardial infarction. J. Am. Coll. Cardiol., 2018, vol. 72, no. 2, pp. 173‒182. doi: 10.1016/j.jacc.2018.04.051.
21. Mebazaa A., Parissis J., Porcher R. et al. Short-term survival by treatment among patients hospitalized with acute heart failure: the global ALARM-HF registry using propensity scoring methods. Intens. Care Med., 2011, vol. 37, no. 2, pp. 290‒301. doi: 10.1007/s00134-010-2073-4. Epub 2010 Nov 18.
22. Mebazaa A., Tolppanen H., Mueller C. et al. Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. Intens. Care Med., 2016, vol. 42, no. 2, pp. 147‒163. doi: 10.1007/s00134-015-4041-5. Epub 2015 Sep 14.
23. Mosterd A., Hoes A. W. Clinical epidemiology of heart failure. Heart, 2007, vol. 93, no. 9, pp. 1137‒1146. doi: 10.1136/hrt.2003.025270.
24. Pirracchio R., Parenica J., Resche Rigon M. et al. GREAT network. The effectiveness of inodilators in reducing short term mortality among patient with severe cardiogenic shock: a propensity-based analysis. PLoS One, 2013, vol. 8, no. 8, pp. e71659. doi: 10.1371/journal.pone.0071659. eCollection 2013.
25. Pollesello P., Ben Gal T., Bettex D. et al. Short-term therapies for treatment of acute and advanced heart failure-why so few drugs available in clinical use, why even fewer in the pipeline? J. Clin. Med., 2019, vol. 8, no. 11. pii: E1834. doi: 10.3390/jcm8111834.
26. Pollesello P., Parissis J., Kivikko M. et al. Levosimendan meta-analyses: Is there a pattern in the effect on mortality? Int. J. Cardiol., 2016, vol. 209, pp. 77‒83. doi: 10.1016/j.ijcard.2016.02.014. Epub 2016 Feb 3.
27. Schumann J., Henrich E.C., Strobl H. et al. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev., 2018, vol. 1, CD009669. doi: 10.1002/14651858.CD009669.pub3.
28. Teerlink J.R., Metra M., Zacà V. et al. Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond. Heart Fail Rev., 2009, vol. 14, no. 4, pp. 243‒253. doi: 10.1007/s10741-009-9153-y.
29. Teerlink J.R. A novel approach to improve cardiac performance: cardiac myosin activators. Heart Fail Rev., 2009, vol. 14, no. 4, pp. 289‒298. doi: 10.1007/s10741-009-9135-0.
30. Zangrillo A., Biondi-Zoccai G., Ponschab M. et al. Milrinone and mortality in adult cardiac surgery: a meta-analysis. J. Cardiothorac. Vasc. Anesth., 2012, vol. 26, no. 1, pp. 70‒77. doi:10.1053/j.jvca.2011.06.022. Epub 2011 Sep 22.
31. Zhai Y., Luo Y., Wu P., Li D. New insights into SERCA2a gene therapy in heart failure: pay attention to the negative effects of B-type natriuretic peptides. J. Med. Genet., 2018, vol. 5, pp. 287‒296. doi: 10.1136/jmedgenet-2017-105120. Epub 2018 Feb 24.
Review
For citations:
Eremenko A.A. Pharmacological therapy of acute heart failure: what is available now and what is expected in future. Messenger of ANESTHESIOLOGY AND RESUSCITATION. 2020;17(2):29-37. (In Russ.) https://doi.org/10.21292/2078-5658-2020-17-2-29-37
Email this article 